MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Open Orphan wins contract for Oxford BioTherapeutics breast cancer study

StockMarketWire.com

Pharmaceutical services group Open Orphan said it had won a contract from Oxford BioTherapeutics related to a study of a treatment for breast cancer.

This phase-one study would assess safety, tolerability, pharmacokinetics and preliminary efficacy.

Open Orphan said its Venn Life Sciences unit would deliver data management and statistics services. 'This deal further demonstrates Open Orphan's ability to execute on its significant pipeline of contracts with important pharmaceutical businesses,' executive chairman Cathal Friel said.



Story provided by StockMarketWire.com